GlassScriptPhysician profile
Shuang Lin
NPI 1689093684
$895.40
in general payments reported to CMS, 2019-2025
12 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.86 · 2023: $136 · 2024: $256 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $325.71 | 2024-2025 | Repatha, Repatha, Evenity |
| Glaxosmithkline, LLC. | $141.22 | 2023-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $139.29 | 2024-2025 | Wegovy, Saxenda |
| Bayer Healthcare Pharmaceuticals INC. | $104.30 | 2025 | |
| Lilly USA, LLC | $45.86 | 2024-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $25.84 | 2025 | Airsupra |
| Philips North America LLC | $22.88 | 2024 | (Ck7) Extended Holter |
| Abbvie INC. | $21.86 | 2019 | |
| Exact Sciences Corporation | $20.60 | 2025 | |
| Baxter Healthcare | $16.03 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Currax Pharmaceuticals LLC | $16.02 | 2025 | Contrave |
| Phadia US INC. | $15.79 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shuang Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.